HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $0 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samjo Capital LLC | 404,963 | $563,000 | 0.48% |
| Cowen Prime Advisors LLC | 332,197 | $462,000 | 0.19% |
| ARMISTICE CAPITAL, LLC | 834,054 | $1,159,000 | 0.02% |
| Nantahala Capital Management | 285,963 | $397,000 | 0.02% |
| HighMark Wealth Management LLC | 6,966 | $10,000 | 0.01% |
| UBS Group AG | 4,000 | $6,000 | 0.00% |
| OSAIC HOLDINGS, INC. | 13 | $0 | 0.00% |
| WELLS FARGO & COMPANY/MN | 41 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 46,039 | $63,000 | 0.00% |